Bioforce Nanosciences Holdings Operating Expenses Growth & History (BFNH)
Bioforce Nanosciences Holdings's operating expenses was $489,951 for fiscal 2025.
View full Bioforce Nanosciences Holdings company overviewBioforce Nanosciences Holdings annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $489,951 | −$486 | −0.10% |
| 2024 | 2024-12-31 | $490,437 | $18,484 | +3.92% |
| 2023 | 2023-12-31 | $471,953 | −$13,561 | −2.79% |
| 2022 | 2022-12-31 | $485,514 | −$16,441 | −3.28% |
| 2021 | 2021-12-31 | $501,955 | −$157.9M | −99.68% |
| 2020 | 2020-12-31 | $158.4M | $158.4M | +311127.46% |
| 2019 | 2019-12-31 | $50,898 | −$20,507 | −28.72% |
| 2018 | 2018-12-31 | $71,405 | $38,889 | +119.60% |
| 2017 | 2017-12-31 | $32,516 | — | — |
Bioforce Nanosciences Holdings quarterly operating expenses
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $262,330 | $139,549 | +113.66% |
| Q1 2026 | 2026-03-31 | $117,733 | −$15,724 | −11.78% |
| Q4 2025 | 2025-12-31 | $117,798 | −$5,362 | −4.35% |
| Q3 2025 | 2025-09-30 | $115,915 | −$6,109 | −5.01% |
| Q2 2025 | 2025-06-30 | $122,781 | $8,341 | +7.29% |
| Q1 2025 | 2025-03-31 | $133,457 | $2,644 | +2.02% |
| Q4 2024 | 2024-12-31 | $123,160 | $8,750 | +7.65% |
| Q3 2024 | 2024-09-30 | $122,024 | $8,417 | +7.41% |
| Q2 2024 | 2024-06-30 | $114,440 | $509 | +0.45% |
| Q1 2024 | 2024-03-31 | $130,813 | $808 | +0.62% |
| Q4 2023 | 2023-12-31 | $114,410 | −$325 | −0.28% |
| Q3 2023 | 2023-09-30 | $113,607 | −$8,980 | −7.33% |
| Q2 2023 | 2023-06-30 | $113,931 | −$1,853 | −1.60% |
| Q1 2023 | 2023-03-31 | $130,005 | −$2,403 | −1.81% |
| Q4 2022 | 2022-12-31 | $114,735 | −$5,966 | −4.94% |
| Q3 2022 | 2022-09-30 | $122,587 | $8,727 | +7.66% |
| Q2 2022 | 2022-06-30 | $115,784 | −$6,531 | −5.34% |
| Q1 2022 | 2022-03-31 | $132,408 | −$12,671 | −8.73% |
| Q4 2021 | 2021-12-31 | $120,701 | −$1,864 | −1.52% |
| Q3 2021 | 2021-09-30 | $113,860 | −$4,062 | −3.44% |
| Q2 2021 | 2021-06-30 | $122,315 | −$4,395 | −3.47% |
| Q1 2021 | 2021-03-31 | $145,079 | −$157.9M | −99.91% |
| Q4 2020 | 2020-12-31 | $122,565 | $102,394 | +507.63% |
| Q3 2020 | 2020-09-30 | $117,922 | $109,866 | +1363.78% |
| Q2 2020 | 2020-06-30 | $126,710 | $118,581 | +1458.74% |
| Q1 2020 | 2020-03-31 | $158.0M | $158.0M | +1086692.45% |
| Q4 2019 | 2019-12-31 | $20,171 | — | — |
| Q3 2019 | 2019-09-30 | $8,056 | −$179 | −2.17% |
| Q2 2019 | 2019-06-30 | $8,129 | −$20,817 | −71.92% |
| Q1 2019 | 2019-03-31 | $14,542 | — | — |
| Q3 2018 | 2018-09-30 | $8,235 | — | — |
| Q2 2018 | 2018-06-30 | $28,946 | — | — |
Bioforce Nanosciences Holdings operating expenses trends
Over the last five fiscal years, Bioforce Nanosciences Holdings's operating expenses decreased from $158.4M to $489,951, a change of −$157.9M. The latest reported quarter, Q2 2026, shows $262,330.
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Bioforce Nanosciences Holdings source filings ↗